Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

717 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.
Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B; CHIC 304 International Liver Study Group. Neuhaus P, et al. Among authors: korn a. Liver Transpl. 2002 Feb;8(2):132-42. doi: 10.1053/jlts.2002.30302. Liver Transpl. 2002. PMID: 11862589 Free article. Clinical Trial.
Basiliximab in pediatric liver transplantation: a pharmacokinetic-derived dosing algorithm.
Kovarik JM, Gridelli BG, Martin S, Rodeck B, Melter M, Dunn SP, Merion RM, Tzakis AG, Alonso E, Bucuvalas J, Sharp H, Gerbeau C, Chodoff L, Korn A, Hall M. Kovarik JM, et al. Among authors: korn a. Pediatr Transplant. 2002 Jun;6(3):224-30. doi: 10.1034/j.1399-3046.2002.01086.x. Pediatr Transplant. 2002. PMID: 12100507 Free article. Clinical Trial.
A multicenter, open-label, pharmacokinetic/pharmacodynamic safety, and tolerability study of basiliximab (Simulect) in pediatric de novo renal transplant recipients.
Offner G, Broyer M, Niaudet P, Loirat C, Mentser M, Lemire J, Crocker JF, Cochat P, Clark G, Chodoff L, Korn A, Hall M. Offner G, et al. Among authors: korn a. Transplantation. 2002 Oct 15;74(7):961-6. doi: 10.1097/00007890-200210150-00010. Transplantation. 2002. PMID: 12394837 Clinical Trial.
Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation.
Lawen JG, Davies EA, Mourad G, Oppenheimer F, Molina MG, Rostaing L, Wilkinson AH, Mulloy LL, Bourbigot BJ, Prestele H, Korn A, Girault D; Simulect International Study Group. Lawen JG, et al. Among authors: korn a. Transplantation. 2003 Jan 15;75(1):37-43. doi: 10.1097/00007890-200301150-00007. Transplantation. 2003. PMID: 12544868 Clinical Trial.
Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine.
Matl I, Bachleda P, Lao M, Michalský R, Navrátil P, Treska V, Prestele H, Matthisson M, Korn A. Matl I, et al. Among authors: korn a. Transpl Int. 2003 Jan;16(1):45-52. doi: 10.1007/s00147-002-0478-x. Epub 2002 Nov 22. Transpl Int. 2003. PMID: 12545341 Clinical Trial.
Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.
Neumayer HH, Paradis K, Korn A, Jean C, Fritsche L, Budde K, Winkler M, Kliem V, Pichlmayr R, Hauser IA, Burkhardt K, Lison AE, Barndt I, Appel-Dingemanse S. Neumayer HH, et al. Among authors: korn a. Br J Clin Pharmacol. 1999 Nov;48(5):694-703. doi: 10.1046/j.1365-2125.1999.00085.x. Br J Clin Pharmacol. 1999. PMID: 10594471 Free PMC article. Clinical Trial.
717 results